AVITA Medical Study Shows PermeaDerm Cuts Wound Treatment Costs 70% Vs Allograft

PermeaDerm study delivers 70% cost advantage over allograft with comparable outcomes

AVITA Medical (NASDAQ: RCEL, ASX: AVH) has reported positive results from its multicenter, randomized controlled PermeaDerm-I clinical study, released on 18 August 2026.

The study demonstrated that PermeaDerm®, a biosynthetic wound matrix, delivered a 70% economic advantage over allograft based on product cost per percent of total body surface area treated, meeting its primary endpoint with statistical significance (p<0.001) alongside clinically comparable outcomes.

The findings strengthen AVITA’s acute wound care portfolio, positioning PermeaDerm as an economically advantaged alternative for wound temporization. Management will host a Key Opinion Leader (KOL) webinar at 4:30 p.m. ET on 18 August 2026 to review the data.

The primary endpoint: 70% lower cost per %TBSA treated

The PermeaDerm-I study met its primary endpoint by demonstrating statistically significant superiority (p<0.001) for mean cost per percent total body surface area (%TBSA) treated. This measure captures the product cost required to treat each 1% of a patient’s body surface, a practical benchmark for hospital economics.

Mean treatment cost was $148.70 for every 1% TBSA treated with PermeaDerm, compared with $497.10 for cadaveric allograft. That equates to a saving of approximately $348 per %TBSA, or a 70% economic advantage.

For hospitals managing burn and acute wound patients, where large surface areas may require temporary coverage, the per-unit savings could accumulate meaningfully across a course of treatment. The result provides quantifiable economic evidence to support commercial adoption.

Clinical outcomes matched allograft with a simpler workflow

While the cost advantage was the standout finding, clinical outcomes between the two treatment groups were comparable. The study did not claim clinical superiority for PermeaDerm on healing measures, but rather demonstrated comparable outcomes with a more streamlined workflow.

Key clinical and operational results included:

• Approximately 94% of PermeaDerm patients achieved at least 95% graft take one week following autografting, comparable to allograft

• All patients in both groups achieved 95% or greater wound healing by eight weeks

• A 95.7% reduction in preparation time by eliminating tissue tracking, thawing, and meshing

• Comparable application time in the operating room

• No adverse events were attributed to PermeaDerm during the study

The logistical simplicity of an off-the-shelf product removes several steps that traditionally accompany allograft use, potentially reducing operational burden on burn centres.

Dr Anju Saraswat

“Temporary wound coverage is a critical step between excision and definitive closure when a wound bed is not yet ready for autograft placement,” said Anju Saraswat, MD, Associate Burn Director and Assistant Professor of Surgery at Atrium Health Wake Forest Baptist Burn Center and study investigator. “These results demonstrate that PermeaDerm provided clinical performance comparable to allograft with the added benefit of product transparency enabling direct visualization of the wound bed. By eliminating tissue bank logistics and preparation time, PermeaDerm offers a more efficient approach to wound temporization without any compromise to healing outcomes and reducing cost.”

Dr Saraswat serves as Associate Burn Director and Assistant Professor of Surgery at Atrium Health Wake Forest Baptist Burn Center and was a study investigator.

What is PermeaDerm and why wound temporization matters

PermeaDerm is a biosynthetic, transparent bilayer wound matrix designed to provide temporary wound coverage during the period between surgical excision and definitive closure. It protects and stabilises the wound while allowing clinicians to visualise the wound bed without removing the product.

Wound temporization refers to the bridging step before an autograft, used when the wound bed is not yet ready for a patient’s own skin to be applied. The transparency of the matrix allows clinicians to monitor healing directly, avoiding disruption to the wound.

From an adoption standpoint, off-the-shelf availability removes the tissue-bank logistics, including thawing and tracking, that can burden hospitals. This practical convenience may serve as a driver for uptake. PermeaDerm sits alongside Cohealyx® and RECELL® within AVITA’s broader acute wound care portfolio.

Cohealyx interim study results published earlier in 2026 showed a mean time to skin grafting of 13.6 days, approximately 20 days faster than a real-world benchmark, with 90% investigator satisfaction across 40 patients, reinforcing the clinical evidence base being built around AVITA’s dermal matrix portfolio.

Study design at a glance

The PermeaDerm-I trial was structured as follows:

1. A post-market multicenter, randomized controlled trial (PermeaDerm-I, NCT06750809)

2. Enrolled 40 patients across 11 U.S. burn centers

3. Eligible wounds involved up to 30% TBSA

4. Following excision, patients were randomized to receive either PermeaDerm or cadaveric allograft before definitive split-thickness skin grafting

5. Patients were followed for eight weeks following definitive closure

6. At final follow-up, all responding investigators and patients reported satisfaction, rated as satisfied or very satisfied

Investment significance and next steps

The PermeaDerm-I study builds both clinical and economic evidence supporting PermeaDerm as what AVITA describes as a “modern alternative to allograft,” reinforcing the company’s differentiated acute wound care portfolio.

Commercially, AVITA holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm in the U.S. PermeaDerm® is a registered trademark owned by Stedical Scientific, Inc.

RECELL GO’s UK clinical debut at Stoke Mandeville Hospital produced complete graft take and zero post-discharge complications across 17 burn and reconstructive surgery patients, adding to the body of real-world evidence accumulating across AVITA’s wound care platform as it scales internationally.

Cary Vance, President & CEO

“The PermeaDerm-I study establishes compelling clinical and economic evidence supporting PermeaDerm as a modern alternative to allograft,” said Cary Vance, President and Chief Executive Officer of AVITA Medical. “By combining comparable clinical performance with meaningful economic value and a simpler workflow, we believe PermeaDerm addresses an important need for hospitals while strengthening AVITA’s differentiated acute wound care portfolio.”

The next step is the KOL webinar on 18 August 2026 at 4:30 p.m. ET, featuring Dr Anju Saraswat and Dr Christina Sharon, Burn and Acute Care Surgeon and Burn Center Director at Baton Rouge General. A replay will be available shortly after the event under the Events & Presentations section of the AVITA Medical website.

Don’t Miss the Next Healthcare Breakthrough on ASX

Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis so the work is already done. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to get started today.